Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Lead
National Institute of Allergy and Infectious Diseases (NIAID)
Study Description: This is a phase 1/2, non-randomized study of a single infusion of autologous hematopoietic stem/progenitor cells (HSPC) base-edited to repair CXCR4 mutations in 10 participants with (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis) WHIM syndrome. Primary Objective: Evaluate safety of treatment with BE-HSPC CXCR4 in participants with WHIM syndrome. Secondary Objectives: Evaluate: * Efficacy. * Genetic correction. * Immune reconstitution. * Clinical efficacy. Exploratory Objective: Evaluate off-target (OT) editing activity. Primary Endpoint: Safety assessed by: * Incidence of adverse events (AEs) for each participant. * Evaluate overall incidence of AEs for the study. * Incidence of serious adverse events (SAEs). Secondary Endpoints (24 months post-study agent infusion): * Efficacy: \>= 5% gene edited circulating myeloid cells by 12 months after BE HSPC infusion. * Gene correction: --Frequency of corrected alleles in peripheral blood cells (such as myeloid, T, B, and natural killer \[NK\] cells). --\>200/microL edited neutrophils by 12 months post receipt of the BE HSPC infusion. * Immune reconstitution: * T, B, and NK cell number improvement from baseline. * B-cell function: immunoglobulin (Ig) production. * Clinical efficacy: Improvement from baseline problems such as recurrent infection, wart burden, gastrointestinal complaints, or immune dysregulation. Exploratory Endpoint: Evaluate for frequency of OTs by high-throughput sequencing (HTS) of the target mutation at the genomic locus 2 years post-infusion.
Age
3–75
Sex
ALL
Healthy volunteers
Not accepted
